Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Smith, K. J.
space
  arrow  Roberts, M. S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

The Cost-Effectiveness of Sildenafil

right arrow Kenneth J. Smith, MD, and Mark S. Roberts, MD, MPP

20 June 2000 | Volume 132 Issue 12 | Pages 933-937

Background: Coverage of sildenafil by health insurance plans is a contentious issue.

Objective: To evaluate the cost-effectiveness of sildenafil treatment for erectile dysfunction.

Design: A Markov decision model to estimate the incremental cost-effectiveness of sildenafil compared with no drug therapy.

Data Sources: Values for the efficacy and safety of sildenafil and quality-of-life utilities were obtained from the published medical literature. Base-case values were chosen to bias against sildenafil use.

Target Population: Men 60 years of age with erectile dysfunction.

Time Horizon: Lifetime.

Perspective: Societal and third-party payer.

Intervention: Sildenafil or no treatment in identical hypothetical cohorts.

Outcome Measures: Cost per quality-adjusted life-year (QALY) gained.

Results of Base-Case Analysis: The cost per QALY gained for sildenafil treatment compared with no therapy was $11 290 from the societal perspective and $11 230 from the third-party payer perspective.

Results of Sensitivity Analysis: From the societal perspective, the cost per QALY gained associated with sildenafil was less than $50 000 if treatment-related morbidity was less than 0.8% per year, mortality was less than 0.55% per year, treatment was successful in more than 40.2% of patients, or sildenafil cost less than $244 per month. The results were sensitive to variation of erectile dysfunction utilities, but cost per QALY gained was less than $50 000 if successful treatment increased utility values by 0.05 or more on a scale of 0 (death) to 1 (perfect health).

Conclusions: In an analysis biased against use of sildenafil, the cost-effectiveness of sildenafil treatment compared favorably with that of accepted therapies for other medical conditions.

Author and Article Information
space

From Mercy Hospital of Pittsburgh and the Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Requests for Single Reprints: Kenneth J. Smith, MD, Department of Medicine, Mercy Hospital of Pittsburgh, 1400 Locust Street, Pittsburgh, PA 15219; e-mail, ksmith{at}pmhs.mercy.org.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Dr. Smith: Department of Medicine, Mercy Hospital of Pittsburgh, 1400 Locust Street, Pittsburgh, PA 15219.

Dr. Roberts: Center for Research on Health Care, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213.

Author Contributions: Conception and design: K.J. Smith, M.S. Roberts.

Analysis and interpretation of the data: K.J. Smith, M.S. Roberts.

Drafting of the article: K.J. Smith.

Critical revision of the article for important intellectual content: K.J. Smith, M.S. Roberts.

Final approval of the article: K.J. Smith, M.S. Roberts.

Collection and assembly of data: K.J. Smith.


Related articles in Annals:

Summaries for Patients
The Cost-Effectiveness of Sildenafil (Viagra)
Annals 2000 132: 933. [Full Text]  

Editorials
Tough Choices: The Cost-Effectiveness of Sildenafil
Michael R. McGarvey
Annals 2000 132: 994-995. [Full Text]  

Letters
Cost-Effectiveness of Sildenafil
Jack Beaird
Annals 2001 134: 249. [Full Text]  

Letters
Cost-Effectiveness of Sildenafil
Peter W. Groeneveld AND Bradford W. Duncan
Annals 2001 134: 249-250. [Full Text]  

Letters
Cost-Effectiveness of Sildenafil
Richard L. Siegel AND Dale B. Glasser
Annals 2001 134: 250. [Full Text]  

Letters
Cost-Effectiveness of Sildenafil
Kenneth J. Smith AND Mark S. Roberts
Annals 2001 134: 250-251. [Full Text]  



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
P. A. Heidenreich, M. A. Gubens, G. C. Fonarow, M. A. Konstam, L. W. Stevenson, and P. G. Shekelle
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1019 - 1026.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
M. McGregor
Cost-utility analysis: Use QALYs only with great caution
Can. Med. Assoc. J., February 18, 2003; 168(4): 433 - 434.
[Full Text] [PDF]


Home page
Diabetes CareHome page
G. De Berardis, M. Franciosi, M. Belfiglio, B. Di Nardo, S. Greenfield, S. H. Kaplan, F. Pellegrini, M. Sacco, G. Tognoni, M. Valentini, et al.
Erectile Dysfunction and Quality of Life in Type 2 Diabetic Patients: A serious problem too often overlooked
Diabetes Care, February 1, 2002; 25(2): 284 - 291.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
A. Gandjour
The Economic Value Of Medical Technology
Health Aff., January 1, 2002; 21(1): 275 - 276.
[Full Text] [PDF]


Home page
JWatch GeneralHome page
Sildenafil Treatment Is Cost-Effective
Journal Watch (General), June 30, 2000; 2000(630): 3 - 3.
[Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2000 by the American College of Physicians.